Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Boehringer Ingelheim's Pradaxa will become one of the leading stroke prevention therapies in the atrial fibrillation drug market, garnering blockbuster sales of $1.3 billion by 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Atrial Fibrillation reveal that novel oral anticoagulants, most notably Pradaxa, Bayer/Johnson & Johnson's Xarelto, and Bristol-Myers Squibb/Pfizer's apixaban will drive significant expansion of the overall atrial fibrillation drug market over the next decade. Pradaxa is expected to launch for atrial fibrillation in 2011, followed soon thereafter by Xarelto. Pradaxa's success will be driven by its first-to-market advantage, coupled with strong results from the landmark RE-LY clinical trial, which were initially reported at last year's European Society of Cardiology Congress.

"Driven by their rapid onset of action and fixed-dosing, novel oral anticoagulants will account for almost three-quarters of the overall atrial fibrillation drug market by 2018," said Decision Resources Analyst Matthew Killeen, Ph.D. "Among the emerging oral anticoagulants in this space, Pradaxa, Xarelto and apixaban will enjoy the most success and their availability will trigger gradual erosion of the market share of vitamin K antagonists such as warfarin."

The Pharmacor 2010 findings reveal that, owing to the launches of several novel agents, the atrial fibrillation drug market will increase eightfold from $780 million in 2008 to $6.3 billion in 2018 in the world's major pharmaceutical markets.

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

  registered trademarks of their respective holders.      For more information, contact:    Decision Resources, Inc.   Christopher Comfort   781-296-2597   ccomfort@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort, Decision Resources, Inc., +1-781-296-2597
, ccomfort@dresources.com

In the Acute Coronary Syndrome Drug Market, the Uptake of Eli Lilly/Daiichi Sankyo's Effient Will Be Constrained by the Widespread Use of Astrazeneca's Brilinta

View Now